Page 33 - TD-3-3

Tumor Discovery Adjuvant immunotherapy in high-risk melanoma

compared with biochemotherapy for the treatment of stage III melanoma (OpACIN-neo): A multicentre,
metastatic melanoma: A meta-analysis of 18 trials involving phase 2, randomised, controlled trial. Lancet Oncol.
2,621 patients. J Clin Oncol. 2007;25(34):5426-5434. 2019;20(7):948-960.
doi: 10.1200/JCO.2007.12.0253 doi: 10.1016/s1470-2045(19)30151-2
10. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant 20. Augustin RC, Luke JJ. Induction Exposure Dose of
ipilimumab versus placebo after complete resection of high- Ipilimumab and Failure of Adjuvant Nivolumab Plus
risk stage III melanoma (EORTC 18071): A randomised, Ipilimumab in Melanoma. J Clin Oncol. 2023;41(3): 443-446.
double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-530. doi: 10.1200/jco.22.01770
doi: 10.1016/s1470-2045(15)70122-1 21. Diab A, Gogas H, Sandhu S, et al. Bempegaldesleukin plus
11. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged nivolumab in untreated advanced melanoma: The open-
survival in stage III melanoma with ipilimumab adjuvant label, phase III PIVOT IO 001 trial results. J Clin Oncol.
therapy. N Engl J Med. 2016;375(19):1845-1855. 2023;41(30):4756-4767.
doi: 10.1056/NEJMoa1611299 doi: 10.1200/jco.23.00172
12. Eggermont AM, Blank CU, Mandala M, et al. Adjuvant 22. Schumacher TN, Schreiber RD. Neoantigens in cancer
pembrolizumab versus placebo in resected stage III immunotherapy. Science. 2015;348(6230):69-74.
melanoma. N Engl J Med. 2018;378(19):1789-1801. doi: 10.1126/science.aaa4971
doi: 10.1056/nejmoa1802357 23. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal
13. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant neoantigen vaccine for patients with melanoma. Nature.
nivolumab versus ipilimumab in resected stage III or IV 2017;547(7662):217-221.
melanoma. N Engl J Med. 2017;377(19):1824-1835. doi: 10.1038/nature22991
doi: 10.1056/nejmoa1709030 24. Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase Ib
14. Abed A, Atkinson V, Bhave P, et al. Management of Resected trial of personalized neoantigen therapy plus anti-PD-1
Stage III/IV Melanoma with Adjuvant Immunotherapy. in patients with advanced melanoma, non-small cell lung
Coreacuk. Available from: https://core.ac.uk/ cancer, or bladder cancer. Cell. 2020;183(2):347-362.e24.
works/123678326 [Last accessed on 2024 Jun 25]. doi: 10.1016/j.cell.2020.08.053
15. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib 25. Sahin U, Derhovanessian E, Miller M, et al. Personalized
in resected, BRAFV600 mutation-positive melanoma RNA mutanome vaccines mobilize poly-specific therapeutic
(BRIM8): A randomised, double-blind, placebo- immunity against cancer. Nature. 2017;547(7662):222-226.
controlled, multicentre, phase 3 trial. Lancet Oncol. doi: 10.1038/nature23003
2018;19(4):510-520.
26. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for
doi: 10.1016/S1470-2045(18)30106-2 clinical response to CTLA-4 blockade in melanoma. N Engl
16. Long GV, Hauschild A, Santinami M, et al. Adjuvant J Med. 2014;371(23):2189-2199.
dabrafenib plus trametinib in stage III BRAF-mutated doi: 10.1056/nejmoa1406498
melanoma. N Engl J Med. 2017;377(19):1813-1823.
27. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-
doi: 10.1056/nejmoa1708539 driven biomarkers to guide immune checkpoint blockade in
17. Dummer R, Hauschild A, Santinami M, et al. Five-year cancer therapy. Nat Rev Cancer. 2016;16(5):275-287.
analysis of adjuvant dabrafenib plus trametinib in stage III doi: 10.1038/nrc.2016.36
melanoma. N Engl J Med. 2020;383(12):1139-1148.
28. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates
doi: 10.1056/nejmoa2005493 of response to CTLA-4 blockade in metastatic melanoma.
18. Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant Science. 2015;350(6257):207-211.
therapy of nivolumab combined with ipilimumab versus doi: 10.1126/science.aad0095
nivolumab alone in patients with resected stage III B-D
or stage IV melanoma (CheckMate 915). J Clin Oncol. 29. A Clinical Study of V940 Plus Pembrolizumab in People with
2022;41:517-527. High-Risk Melanoma (V940-001)-Full Text View-Clinical
Trials. Available from: https://classic.clinicaltrials.gov/ct2/
doi: 10.1200/jco.22.00533 show/NCT05933577 [Last accessed on 2024 Jun 25].
19. Rozeman EA, Menzies AM, Van Akkooi AC, et al. 30. Khattak A, Weber JS, Meniawy T, et al. Distant metastasis
Identification of the optimal combination dosing schedule free survival results from the randomized, phase 2 mRNA-
of neoadjuvant ipilimumab plus nivolumab in macroscopic 4157-P201/KEYNOTE-942 trial. J Clin Oncol. 2023;41(17

Volume 3 Issue 3 (2024) 9 doi: 10.36922/td.3143